PIK3CA Mutations Frequently Coexist With EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup

PLoS ONE - United States
doi 10.1371/journal.pone.0088291
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

EGFR and KRAS Mutations and Disease Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Definitive Radiation Therapy

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2015English

Common and Rare EGFR and KRAS Mutations in a Dutch Non-Small-Cell Lung Cancer Population and Their Clinical Outcome

PLoS ONE
Multidisciplinary
2013English

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

Oncologist
Cancer ResearchMedicineOncology
2015English

EGFR Mutations Status for Non-Small-Cell Lung Cancer Patients

Sveikatos mokslai
2016English

Influence of EGFR-activating Mutations on Sensitivity to Tyrosine Kinase Inhibitors in a KRAS Mutant Non-Small Cell Lung Cancer Cell Line

PLoS ONE
Multidisciplinary
2020English

KRAS, HRAS and EGFR Mutations in Sporadic Sebaceous Gland Hyperplasia

Acta Dermato-Venereologica
DermatologyMedicine
2014English

Prognostic Value of KRAS/TP53/PIK3CA in Non‑small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2019English

Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer With Activating EGFR Mutations

OncoTargets and Therapy
OncologyPharmacology
2016English

Patterns of EGFR, HER2, TP53, and KRAS Mutations of P14arf Expression in Non-Small Cell Lung Cancers in Relation to Smoking History

Cancer Research
Cancer ResearchOncology
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy